^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GC101 TIL

i
Other names: tumor infiltrating lymphocytes, GC101 TIL, autologous tumor infiltrating lymphocytes
Associations
Trials
Company:
Gencells Therapeutics
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
5ms
New P1 trial
|
GC101 TIL
5ms
Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date • Metastases
|
cyclophosphamide • GC101 TIL
over2years
Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. (PubMed, J Immunother Cancer)
Omitting high dose of IL-2, she received intravenous dose of cyclophosphamide (20 mg/kg) for 3 days, approximately 48 hours before receiving the intravenous infusion of TILs. These results illustrated the potential value of modified lymphodepletion, followed by TILs for the treatment of patients with cervical cancer with local recurrence. Trial registration number, NCT04766320.
Journal • Tumor-Infiltrating Lymphocyte
|
IL2 (Interleukin 2)
|
PD-1 expression
|
cyclophosphamide • GC101 TIL